Antoine C. El Khoury, PhD

This poster was presented at the 31st annual Psych Congress, held Oct. 25-28, 2018, in Orlando, Florida. Background: There is limited literature on treatment patterns, healthcare resourc...

Charmi Patel , BS , RN, BSN, MPH;

Antoine C. El Khoury , PhD;

Ahong Huang , BS , MS;

Kruti Joshi , MPH, MD;

Li Wang , MS, MBA, PhD, MA;

Onur Baser , PhD, ScM, BS , MS;

03/01/2019

Real-World Outcomes Post-Transition to Once-Every-Three-Month Paliperidone Palmitate in Patients With Schizophrenia Within US Commercial and Managed Care Plans

Background: Medication non-adherence is common for patients with schizophrenia. Decreasing dosing frequency of patients adequately treated with once-monthly paliperidone palmitate (PP1M) ...

Antoine C. El Khoury , PhD;

Bruno Emond , MA;

Maryia Zhdanava , MA;

Kruti Joshi , MPH, MD;

Charmi Patel , BS , RN, BSN, MPH;

Patrick Lefebvre , MA;

Laura Morrison , MPH;

Dominic Pilon , MA;

Neeta Tandon , MA;

03/01/2019

Factors Associated With Treatment Initiation With Atypical Long-acting Injectable Antipsychotics Among Medicaid Patients With Schizophrenia

Objectives: Investigate demographic, clinical, and economic factors associated with treatment initiation of paliperidone palmitate (PP) and aripiprazole LAI (ALAI) in Medicaid patients wi...

Antoine C. El Khoury , PhD;

Charmi Patel , BS , RN, BSN, MPH;

Nancy Connolly , MPH;

Edward Kim , MD, MBA;

Qian Cai , MSPH, MS;

Ozgur Tunceli , PhD;

03/01/2019

Encounters With the Criminal Justice System in Patients With Schizophrenia or Schizoaffective Disorders Treated With Long Acting Therapy at a Community Mental Health Service Facility

Purpose: This study assessed the association between the use of Long-acting injectable (LAI) anti-psychotic drugs and encounters with the criminal justice system (CJS) among patients rece...

Madhav Bhatta , PhD;

Saroj Bista , BPharm;

Antoine C. El Khoury , PhD;

Eric Hutzell , MPH;

Douglas Smith , MD;

Neeta Tandon , MA;

03/01/2019

Treatment Discontinuation of Long-Acting Injectables or Oral Atypical Antipsychotics Among Medicaid Recipients With Schizophrenia

OBJECTIVE: Compare treatment discontinuation of atypical long-acting injectables (LAIs) and oral atypical antipsychotics (OAA) in patients with schizophrenia.

Xue Song , PhD;

Antoine C. El Khoury , PhD;

Matthew Brouillette , MPH;

Kruti Joshi , MPH, MD;

David Smith , PhD, MD, MBBS, DPM;

03/01/2019